1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs

Secarna’s Antisense Sweet Spot Offers Deal And IPO Prospects

 
• By Lucie Ellis-Taitt

Jonas Renz, managing director of antisense platform company Secarna, discussed deal making and the company’s outlook in an interview at the recent BIO-Europe Spring partnering conference.

Jonas Renz
Jonas Renz, managing director, Secarna

An IPO could be on the cards in the next couple of years for Secarna, the German developer of antisense oligonucleotides. Set up in 2015, the company has been active on the deal-making front. It offers the kind of platform technology that is in short supply but high demand, managing director and co-founder of the company Jonas Renz told Scrip.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

PureTech Weighs Up Pros And Cons Of Going Private

 
• By Kevin Grogan

The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.

GSK Ramps Up Neuroscience Investment With ABL Brain Shuttle Deal

 
• By Andrew McConaghie

The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.

Epsilogen Hits Antibody Acquisition Trail With TigaTx Takeover

 
• By Kevin Grogan

Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.

More from Business

Taxes, Not Tariffs, Influence US Manufacturing, J&J CEO Says

 
• By Jessica Merrill

The big pharma forecast a $400m expense this year related to tariffs, but those estimates only reflect medtech tariffs already announced, not potential pharma tariffs.

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly

 
• By Andy Smith

The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.

Korean Biotech Roundup: GNT Set For First Direct Korean Biopharma IPO On Nasdaq

 
• By Jung Won Shin

GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.